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Background: Clear cell sarcoma (CCS), initially named malignant melanoma of soft parts, is an aggressive soft tissue
sarcoma (STS) that, due to MITF activation, shares with melanoma the expression of melanocyte differentiation
antigens. CCS is poorly sensitive to chemotherapy. Multi-kinase inhibitors have been used as therapeutic agents. In
the case we report here, treatment with sunitinib induced a long-lasting clinical response that was associated with
an immune activation directed against Melan-A/MART-1 antigen.
Case presentation: A 28 years old female patient with an advanced molecularly confirmed CCS resistant to
conventional chemotherapy was started in January 2012 on sunitinib, 37.5 mg/day, with evidence of radiologic and
metabolic response at the primary and metastatic sites of disease. Pathologic response and loss of the Melan-A/MART-1
antigen were evidenced on residual tumor removed in April 2012. Immunological monitoring performed on patient’s
blood during pharmacological treatment revealed a systemic, Melan-A/MART-1 specific immunity and a low frequency
of immunosuppressive cells. Sunitinib was restarted in May 2012, with a new response, and continued for 11 months
although with repeatedly interruptions due to toxicity. Disease progression and new responses were documented at
each treatment interruption and restart. Sunitinib was definitively interrupted in April 2013 for disease progression.
Conclusion: The analysis of this case proves that antigens expressed by CCS, as for melanoma, can be immunogenic
in vivo and that tumor-antigen specific T cells may exert anti-tumor activity in CCS patient. Thus, manipulation of the
immune response may have therapeutic potential for this STS subtype and immunotherapy approaches, can be
promising therapeutic options for these patients.
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Clear cell sarcoma (CCS) is a very rare and aggressive
soft tissue sarcoma (STS), usually arising from deep soft
tissue or viscera [1], and marked by a very high meta-
static risk resulting in a 5-year overall survival of about
50% [2-4]. In contrast with other STS, and similarly to
melanoma, its metastatic sites include lymph nodes
(LNs). CCS, initially named malignant melanoma of soft* Correspondence: silvia.stacchiotti@istitutotumori.mi.it
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unless otherwise stated.parts [5], are molecularly characterized in most cases by a
specific translocation, t(12;22)(q13;q12), which results in
fusion of the Ewing’s sarcoma gene, EWS, with the cyclic
AMP (cAMP) regulated transcription factor, ATF1, a
member of the cAMP-responsive element binding protein
(CREB) family [6]. The EWS-ATF1 chimeric fusion pro-
tein interacts with the MITF (melanocyte master tran-
scription factor) promoter, thus it directly and aberrantly
activates MITF expression. Consequently, CCS is charac-
terized by the expression of the melanocytic differentiation
markers HMB-45/gp100 and Melan-A/MART-1 [7].
Overall, several immunophenotypic and molecular fea-
tures are shared between CCS and malignant melanoma.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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location and thus, clinical presentation as well as fluores-
cence in situ hybridization (FISH) analysis and reverse
transcription polymerase chain reaction (RT-PCR) for the
specific translocation are crucial to distinguish the two en-
tities. Receptor tyrosine kinase expression/activation [8]
and gene expression analysis [9] indicate that MITF drives
the same down-stream pathways in CCS and in melan-
oma, and that PDGFRβ and c-Met are expressed by CCS
[10,11]. Moreover, BRAF activating mutations have been
occasionally detected in both EWS-ATF1 positive and
negative CCS [8,12,13]. CCS is poorly sensitive to chemo-
therapy and anecdotal responses to regimens containing
dacarbazine, vincristine, anthracycline, cyclophosphamide
and to interferon-alpha-2b [14] have been reported. Based
on the molecular features described above, multi-kinase
inhibitors have been used as therapeutic agents in this
STS and objective responses to sunitinib, and sorafenib
treatments have been recently reported [15,16]. Here we
describe a case of a 28 years old female patient with a
metastatic, translocated CCS who experienced a pro-
longed, objective response to sunitinib malate (hereafter
reported as sunitinib). We consider this case of interest as
objective response to sunitinib correlated with a low fre-
quency of immunosuppressive cells in the periphery, the
presence of a systemic immunity directed against the CCS
associated antigen Melan-A/MART-1 and the in vivo im-
mune selection of post-sunitinib, MART-1 negative
tumor. The analysis of this case proves that antigens
expressed by CCS, as for the melanoma, can be immuno-
genic in vivo and that tumor-antigen specific T cells may
exert anti-tumor activity in vivo.
Case presentation
A female patient aged 28 years presented in 2007 with a
lesion arising from the deep soft tissue of the left foot,
covered by a healthy skin. Prior clinical history was
negative for melanoma. TNM classification at presenta-
tion was: stage 3, e.g. primary lesion arising from soft
tissue of the left foot with positivity of the ipsilateral in-
guinal sentinel LNs. On whole body CT scan there was
no evidence of secondary lesions. Initial treatment con-
sisted of wide excision of the primary tumor (surgery
2007) with diagnosis of clear cell sarcoma (CCS), and
confirmed by the positivity of the FISH analysis for
EWS-ATF1. The patient received sequential hyperther-
mic limb perfusion with melphalan and TNF and the
surgical dissection of the left inguinal-iliac-obturator
LNs. Three of the LNs removed were positive for dis-
ease. Local recurrence and inguinal LN relapse was de-
tected in July 2011 and treated with doxorubicin plus
dacarbazine for 5 cycles with response. Given the evi-
dence of a new disease progression (a loco-regional and
inguinal LN relapse, as confirmed by CT scan and PET)and based on preliminary evidence of sunitinib possible
activity in CCS [15], in January 2012 sunitinib was
started at the dose of 37.5 mg/day, with a tumor partial
response (classified according to RECIST, version 1.1
[17]) to the lesion located on left foot and a complete re-
sponse to metastasis on upper left leg. The response was
confirmed by PET and CT scan (Figure 1). In April 2012,
patient underwent left leg amputation, with evidence of
pathologic response to sunitinib in the surgical speci-
men. In May 2012, sunitinib was restarted and main-
tained at the same dosage till January 2013. During these
months of treatment, sunitinib was repeatedly stopped
due to toxicity, with evidence of rapid disease progres-
sion following treatment interruption and of a new re-
sponse after restoring treatment. From January 2013,
sunitinib was reduced to 12.5 mg/day due to grade 3
cardiac toxicity. After initial disease stabilization, disease
progression occurred marked by a re-growth of previ-
ously responsive tumor lesions and by the evidence of
new lesions to the soft tissues of the left leg and pelvic
LNs. Sunitinib was definitively interrupted in April 2013.
Patient died of disease in February 2014.
Immune-related analysis were performed at the tumor
site and in the peripheral blood of this patient (Table 1).
The expression of the MITF regulated melanocytic antigens
(HMB-45/gp100 and Melan-A/MART-1, Figure 2A) and S-
100 (data not shown) was assessed by immunohistochemis-
try on pre- (surgery December-2010 and November-2011)
and post-sunitinib tumor specimens (surgery April-2012).
Pre-treatment tumor lesions displayed a clear positivity for
all of the analyzed antigens. Conversely, tumor specimen
removed after treatment with sunitinib displayed a selective
loss of MART-1 expression, while it retained the positivity
for HMB-45 and S-100 (Figure 2A). Post-sunitinib tumor
was heavily infiltrated by CD3+ T cells that contained a sig-
nificant proportion of CD8+ T cells. Areas of pathological
regression were clearly evident in association with lympho-
cyte infiltration (Figure 2B). No T cells infiltration were de-
tected in the pre-treated lesion (data not shown). The
in vivo generation of the MART-1 loss antigen variant par-
alleled the presence of anti-MART-1 systemic immunity in
the blood of this CCS patient. Patient’s peripheral blood
mononuclear cells (PBMCs) isolated in the course of suniti-
nib treatment and before surgery (surgery April-2012),
sensitized in vitro with the immunogenic HLA-A*0201 re-
stricted peptide Melan-A/MART-1[27L] displayed the pres-
ence of a remarkable frequency of MART-1 specific CD8+T
cells (7,72%), as monitored by pentamer staining (Figure 3).
These anti-MART-1 specific T cells were functionally
active. MART-1 sensitized PBMC released IFNγ when
stimulated with the target cells loaded with Melan-A/
MART-1-epitope (modified and native) and, import-
antly, they recognized in a MHC restricted fashion
HLA-A*0201+MART1+, but not HLA-A*0201+MART1−
baseline Sunitinib (37.5 mg/day)+8wksBA
C
Sunitinib (37.5 mg/day)
+3 monthsbaseline
Figure 1 Response to sunitinib: FDG-PET and CT scan evaluation. (A) Baseline FDG PET/CT study: sagittal fused PET/CT image showing
abnormal FDG uptakes in the left foot tumor (circle; SUVmax 12.0) and in soft tissue metastatic nodules in the ankle and leg (arrows); (B) After
8 weeks of treatment with SM 37.5 mg/day, PET/CT re-evaluation shows a complete metabolic response of the foot lesion (circle; SUVmax 2.5;
ΔSUV −79%) and the disappearance of the soft tissue nodules. (C) CT scan (venous phase after contrast medium) shows a complete response to
a right inguinal lymph node after 3 months of treatment with sunitinib (green arrow), compared to baseline (red arrow).
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ELIspot assay (Figure 3). Conversely, no T cells specific for
the HLA-A*0201- gp100[210M] peptide were detected in
post-sunitinib PBMCs of the patient applying the same
procedure. All together these evidences strongly supportTable 1 Summary of the immune-related analysis
Date Immune-related
December 2010
(Dec-2010)
biopsy IHC: MART-1/Mel
gp100/HMB-45 +
November 2011 surgery IHC: MART-1/Mel
gp100/HMB-45 +
January 2012
(Jan-2012)
sunitinib
April 2012 surgery IHC: MART-1/Mel
gp100/HMB-45 +
CD3 +; CD8 +
May 2012/April
2013
sunitinib*
Abbreviations: IHC, immunohistochemistry.
Note: *stopped many times due to toxicity with evidence of disease progression fothe hypothesis that the post-sunitinib MART-1 negative
tumor variant is the in vivo outcome of a T cell-mediated
immune selection occurring in CCS patient during suniti-
nib treatment. The anti-MART-1 systemic immunity in
post-sunitinib CCS patients was associated with lowanalysis
an-A +; S-100 +;
an-A +; S-100 +;
Immunological monitoring:
an-A -; S-100 +;
;
• Frequency of immunosuppressive cells
and CD3+ T cell function (Figure 4)
• Presence of Melan-A/MART-1 specific
CD8+ T cells (Figure 3)
llowing treatment interruption and new response after restoring treatment.
Figure 2 Immunohistochemical analysis of tumor antigens expression and T cell infiltration. (A) Hematoxylin and eosin (H&E), Melan-A/
MART-1 and HMB-45/gp100 stainings in pre- (November 2011) and post- (April 2012) sunitinib tumor lesions. (B) Analysis of infiltrating immune T
cells (CD3 and CD8) in sunitinib-treated tumor. Higher magnification in a shows area of pathologic tumor regression associated with lymphocyte
infiltration; Bottom panels show CD3 and CD8 stainings; square b reports the high magnification of area infiltrated by CD8+ T cells. All scale bars
indicate 50 μm.
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b+HLADRneg/low monocytic myeloid-derived suppressor
cells (mMDSCs), a population expanded in cancer pa-
tients, including melanoma [18-21]. Multi-parametric flow
cytometry indicate that PBMCs collected during sunitinib
treatment displayed a frequency of mMDSCs, comparable
to that of healthy donors (HD) (Figure 4). Moreover, this
low percentage of mMDSCs correlates with functional
active convenctional T lymphocytes measured ex vivo as
IL-2 and IFN-γ produced by CD3+ cells upon TCR stimu-
lation (Figure 4). A strong increase in the number of circu-
lating mMDSC and functionally impaired T cells was
detected at the time of disease progression. Conversely, re-
duced frequency of CD3+CD4+CD25hiFoxp3hi regulatory
T cells (Tregs) comparable to that of HD persisted all
along the drug treatment (data not shown).Conclusions
We described herein the case of a CCS (HLA-A*0201)
patient with advanced disease that displayed a long-
lasting response to treatment with the anti-angiogenic
drug sunitinib. Based on the expression and the activa-
tion status of PDGFRβ in CSC, documented by our and
other groups [8,15], sunitinib likely exerts a direct inhib-
ition of the PDGFRβ-driven pathway in the tumor cells
of the patient here studied. However, along with the ef-
fect on the tumor cells, this case report documented that
in this patient, objective response during sunitinib treat-
ment was associated to traits of tumor-specific immun-
ity. The study of this clinical case shows that antigen
expresses by CCS can be immunogenic and indicates
that manipulation of the immune response may have
therapeutic potential in this STS subtype. As melanoma,
Figure 3 (See legend on next page.)
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Figure 3 Phenotypic and functional analysis of tumor antigen-specific CD8 T cells. (A) Phenotypic analysis of pentamer+ CD8+ T cells after
sensitization with the HLA2-A*0201 restricted-modified peptides (Melan-A/MART-1[27L] or gp100[210M]). (B) The tumor specificity of peptide sensitized T
cells was assessed by measuring IFN-γ secretion (Enzyme-Linked ImmunoSpot (ELISpot) assay) upon stimulation with HLA-A*0201-restricted Melan A/
MART-1 (modified or native)-pulsed (2 μmol/L) lymphoblastoid T2 cell line or HLA-matched HLA-A*0201+MART1+ tumor cells (#501mel and #624.38mel)
pretreated or not with the anti-HLA class I (W6/32) mAb. Moreover, T cells were also incubated with HLA-mismatched allogeneic HLA-A*0201−MART1+
(#624.28mel) or HLA-A*0201+MART1− melanoma cells (#A375mel). The irrelevant peptide NEF[180–189] was used as negative control. P values were
calculated by two-tailed t test.
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genes encoding for the melanoma differentiation anti-
gens. Thus, we look at the presence of antigen-specific
response in this CCS patient. Interestingly, we observed
that tumor specimen resected after treatment with suni-
tinib had lost the expression of MART-1 antigen. The
in vivo generation of MART-1 loss variant was associ-
ated to a CD3 + CD8+ T cell infiltration and to the pres-
ence of areas of pathologic regression, thus suggesting
the in vivo occurrence of MART1-specific response. This
immune contexture at the tumor site was paralleled by
the finding that functionally active anti-MART-1 T cells
were detectable in the blood of this patients collected
during sunitinib treatment. To our knowledge this is the
first report documenting the in vivo immunogenicity ofFigure 4 Frequency of circulating mMDSCs and T cell function
during sunitinib treatment. Histograms show the frequencies of
CD14+HLADRneg/low (mMDSCs) in live gated CD14+CD11b+ cells of
patient’s PBMCs. Average level of mMDSC frequency of healthy
donors (HD) is reported. Patient’s PBMCs were assayed for IFN-γ
(red line) and IL-2 (blue line) production in response to overnight
activation with anti-CD3/CD28-coated beads. Dotted horizontal lines
(IFN-γ (red) and IL-2 (blue)) indicate the average level of cytokine-
producing T cells in HD.CCS tumor. The immune response in the CSC patient
studied in this report was directed toward Melan-A/
MART-1. No specific immunity directed against the less
immunogenic differentiation antigen gp100 was devel-
oped and, as expected, reactivity for HMB-45/gp100 was
maintained in post-sunitinib surgical specimen. These
findings are in line with the observation that Melan-A/
MART-1/HLA-A*0201 restricted peptide behaves as
immune-dominant epitope in melanoma patients and a
high proportion (about 70%) of advanced stage III-IV
melanoma patients display a natural anti-Melan-A/
MART-1 immunity [22]. In the peripheral blood of this
patient, we observed that sunitinib treatment sustained a
down-modulation in the frequency of immune suppres-
sive cells, Tregs and mMDSCs, and a parallel activation
of T cell functions evaluated by the capacity of CD3+ T
cells to release Th1 cytokines in response to a polyclonal
stimulation. The immunomodulatory function of suniti-
nib has been clearly documented in other human tumors
and we confirmed this activity in the setting of CCS
[23,24]. However, our observations also suggest that the
release in the immune suppression induced by sunitinib
may have unleashed anti-tumor immunity in this CCS
patient. Indeed, this hypothesis is in agreement with the
observation that, in melanoma patients, antigen-specific
responses are prevented by the presence of high fre-
quency of circulating mMDSCs [25]. By contrast a de-
crease of their number favors the clinical response in
patients treated with immunotherapy [26].
In conclusion, this case shed light on immune-
similarities between CCS and melanoma, and indicates
that manipulation of the immune response in this STS
subtype likely evokes antigen-specific response. In
addition to T cells specific for MITF-regulated antigens,
anti-tumor immunity may potentially include also T cells
recognizing unique, mutation-specific determinants. As
previously shown by in vitro immunological assays [27],
the chimeric protein encoded by the specific chromo-
some translocation of CCS is certainly a source for these
type of antigens and it is well known that immune re-
sponse directed to mutated antigens plays a crucial role
in determining tumor rejection and clinical response in
cancer patients under immunotherapy regimens [28,29].
Although generalized conclusion cannot be depicted
from a single case, these findings suggest that
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specific vaccine and antibodies directed to immuno-
logical checkpoints, such as ipilimumab (anti-CTLA4)
or nivolumab (anti-PD1), may offer, alone or in associ-
ation with targeted-therapies, a new therapeutic option
for advanced CCS patients, for which no successful
therapies are currently available.
Materials and methods
PBMCs and cell lines
PBMCs were obtained by Ficoll density gradient centri-
fugation followed by cryopreservation. 501mel cell line
was generated as previously described [30], 624.38mel
and 624.28mel were cloned as previously described [31].
A375mel and the lymphoblastoid cell line T2 were ob-
tained from the American Type Cell Culture (ATCC).
All these cell lines were cultured in RPMI 1640 (Lonza)
supplemented with 10% FCS (Lonza), Hepes and antibi-
otics. For tumor cell line immuno-phenotyping, the
FITC–labeled BB7.2 monoclonal antibody (BD Bios-
cences, San Diego, CA) was used.
Immunohistochemical analysis of antigen expression in
tumor biopsies
5-μm thick formalin-fixed, paraffin-embedded tissue sec-
tions were processed for IHC staining. The monoclonal
antibodies used were directed against the following anti-
gens: anti-S100, anti-Melan-A/MART-1, anti-HMB-45/
gp100, anti-CD8 (DAKO) and anti-CD3 (Novocastra).
Lymphocyte stimulation and Enzyme-Linked ImmunoSpot
(ELISpot) assay
PBMCs isolated from the patient were thawed and cul-
tured in the presence of the HLA2-A*0201 restricted-
modified peptides (Melan-A/MART-1[27L] or gp100[210M])
(2 μmol/L) plus 60 IU/mL IL-2 (Proleukin). The cells were
tested every 10 to 14 days by flow cytometry analysis for
the enrichment of CD8+pentamer+ T cells. To assess their
reactivity against tumor cells, IFN-γ release was deter-
mined by ELISpot assay (Mabtech) in the presence of
MART1 (modified or native)-pulsed (2 μmol/L) lympho-
blastoid T2 cell line or HLA-A*0201+/− (MART+/−) mel-
anoma cell lines. HLA class I-blocking experiments
required preincubation of target cells with the W6/32
mAb.
Flow cytometry analysis of antigen specific T cells and
immunosuppressive cells
Phenotypic characterization of T cell cultures was done
by the multiparametric flow cytometry analysis using the
following mAbs: anti-CD8-Krome Orange (Beckman
Coulter, Brea, CA), anti-CD4-APC (BD Bioscences), the
HLA-A*0201 multimers were provided by Proimmune
Ltd. Tregs and MDSCs frequencies were determined bymulti-colour immunofluorescence staining of thawed
PBMCs, excluding dead cells using the LIVE-DEAD®
Fixable Violet Dead Cell Stain Kit (Life Technologies,
Carlsbad, CA). For surface staining, after treatment with
FcR Blocking Reagent (Miltenyi, Bergisch-Gladbach,
Germany), cells were incubated with the following anti-
bodies for 30 minutes at 4°C :APCH7-conjugated anti-
CD4, PE-Cy7-conjugated anti-CD25 (for detecting Treg);
APCH7 conjugated anti-CD14, PE-Cy7-conjugated anti-
CD11b, PE-conjugated anti-HLADR (for detecting
mMDSC). All antibodies were from BD Bioscences except
PE-Cy7-conjugated anti-CD11b (from Beckman Coulter).
For Treg analysis, intracellular staining with APC-
conjugated anti-Foxp3 (eBioscience) or the proper isotype
control (rat IgG2a) was performed. Lymphocytes activated
overnight with anti-CD3/CD28 beads (DynaBeads® CD3/
CD28 T cell Expander, Invitrogen Dynal AS, Oslo,
Norway) in the presence of 1 μl/ml Golgi Plug (BD Biosci-
ences) were stained for the cell surface marker CD3. The
cells were then washed, fixed and permeabilized with
Cytofix/Cytoperm buffer (BD Biosciences) and stained
with a 488-labelled anti-IFN-γ (BioLegend), PE-labelled
anti-IL-2 (BD Biosciences). Data acquisition was per-
formed using a Gallios™ (Beckman Coulter) flow cyt-
ometer, and the Kaluza® software (Tree Star Inc, Ashland,
OR) was used for data analysis.
Consent
Written informed consent was obtained from the patient.
A copy of the written consent is available for review by the
Editor of this journal.
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